Aβ status assessment in a hypothetical scenario prior to treatment with disease‐modifying therapies: Evidence from 10‐year real‐world experience at university memory clinics

Abstract INTRODUCTION With the advent of disease‐modifying therapies, accurate assessment of biomarkers indicating the presence of disease‐associated amyloid beta (Aβ) pathology becomes crucial in patients with clinically suspected Alzheimer's disease (AD). We evaluated Aβ levels in cerebrospinal fl...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Matthias Brendel, Tandis Parvizi, Johannes Gnörich, Christof Elias Topfstedt, Katharina Buerger, Daniel Janowitz, Boris‐Stephan Rauchmann, Robert Perneczky, Carolin Kurz, Dirk Mehrens, Wolfgang G. Kunz, Julia Kusche‐Palenga, Agnes Bernadette Kling, Antonia Buchal, Elizabet Nestorova, Sara Silvaieh, Raphael Wurm, Tatjana Traub‐Weidinger, Sigrid Klotz, Günther Regelsberger, Axel Rominger, Alexander Drzezga, Johannes Levin, Elisabeth Stögmann, Nicolai Franzmeier, Günter U. Höglinger
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2024-10-01
Edice:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Témata:	Alzheimer's disease biomarkers cerebrospinal fluid dementia positron emission tomography real world
On-line přístup:	https://doi.org/10.1002/dad2.70031
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!